Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Ark Invest’s Spot Bitcoin ETF Inches Closer To SEC Approval
-
Bitcoin Slumps Below $23,000 As Investors Assess Impact of Federal Reserve Interest Rate Moves
-
Cardio Diagnostics Jumps After Launching Blood Test For Early Detection Of Coronary Heart Disease
-
Bitcoin Enthusiast Implants NFC Chip In His Hand to Make BTC Lightning Payments
-
Bitcoin Futures Soar on Deribit and CME